Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Oxybutynin Chloride · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Oxybutynin Chloride Extended-Release Tablets, 15 mg |
| 2 | ACTIVE_COMPARATOR | Ditropan XL® Extended-release tablets, 15 mg |
| Name | Type | Description |
|---|---|---|
| Oxybutynin Chloride Extended-Release Tablets, 15 mg | DRUG | 15mg, single dose fasting |
| Ditropan XL® Extended-release tablets, 15 mg | DRUG | 15mg, single dose fasting |
| Oxybutynin Chloride Extended-release Tablets 5 mg | DRUG | 4x5mg, single dose fed |
| Ditropan XL® Tablets 5 mg | DRUG | 4x5mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days prior to the start of the study and on the even...
Oxybutynin Chloride is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is an antagonist that targets the CHRM2 and CHRM3 receptors. The drug is in Phase 1 clinical development, and its specific indications are currently undisclosed.
Oxybutynin Chloride targets the CHRM2 and CHRM3 receptors. It acts as an antagonist at these targets. This mechanism of action is characteristic of small molecule drugs in its class.
Oxybutynin Chloride is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for the clinical development of this drug candidate.
Oxybutynin Chloride is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trials have been completed, and no active trials are currently ongoing.
Oxybutynin Chloride has been studied in three completed Phase 1 trials: NCT00650481, NCT00649272, and NCT00648843. These trials enrolled a total of 168 healthy volunteers in the United States. All trials were randomized and active-controlled, comparing the drug to Ditropan XL tablets.
Yes, Oxybutynin Chloride is also known as Oxybutynin Chloride Extended-release Tablets 5 mg and Oxybutynin Chloride Extended-Release Tablets, 15 mg. These alternative names refer to the same drug candidate developed by Viatris Inc.